Revolution Medicines, Inc. (RVMD) Stock Price & Analysis
Revolution Medicines, Inc. (RVMD) rose 0.25% to USD 189.23 as of July 25, 2026 at 03:45 UTC, according to Nexqual real-time market data.
RVMD last closed at USD 188.75; the session ranged USD 185.89–190.5 on volume of 1,232,210 shares. Market capitalization is $40.23B, with a 52-week range of USD 34–193.83 (NMS). Source: Nexqual, July 25, 2026 at 03:45 UTC.
Key Statistics (as of July 25, 2026 at 03:45 UTC)
| Price | USD 189.23 |
|---|---|
| Change | ▲ 0.25% (up) |
| Previous Close | USD 188.75 |
| Open | USD 189.23 |
| Day Range | USD 185.89 – 190.5 |
| 52-Week Range | USD 34 – 193.83 |
| Volume | 1,232,210 shares |
| Market Cap | $40.23B |
| Exchange | NMS |
Technical Analysis (RVMD)
Nexqual's technical model rates RVMD "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:45 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.1 (neutral) |
| vs SMA50 | Above (USD 167.69) |
| MACD | 5.22 (positive) |
Analyst Ratings (RVMD)
Wall Street analysts rate RVMD "Strong Buy" based on 21 analysts, with a mean price target of USD 207 (range USD 151–263), per Nexqual as of July 25, 2026 at 03:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 21 |
| Mean Target | USD 207 |
| High Target | USD 263 |
| Low Target | USD 151 |
| Buy / Hold / Sell | 21 / 1 / 0 |
Earnings (RVMD)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -2.06 |
| Revenue Estimate | $15.47M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.29 vs est -1.84 ▼ miss |
| 2025-12-31 | USD -1.86 vs est -1.56 ▼ miss |
| 2025-09-30 | USD -1.61 vs est -1.41 ▼ miss |
| 2025-06-30 | USD -1.31 vs est -1.12 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:45 UTC.
Financials & Fundamentals (RVMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -76.67% |
| Debt / Equity | 29.15 |
| Current Ratio | 6.8 |
| Total Cash | $1.91B |
| Total Debt | $437.27M |
| Free Cash Flow | $-606.37M |
Source: Nexqual, July 25, 2026 at 03:45 UTC.
Financial Health Score (RVMD)
Nexqual rates Revolution Medicines, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:45 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $1.91B cash vs $437M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$1.06B |
| Efficiency | Critical — ROE -77%, ROA -37.5% |
Ownership (RVMD)
| Insider Ownership | +1.90% |
|---|---|
| Institutional Ownership | +97.52% |
| Shares Outstanding | 212.60M |
| Float | 194.11M |
| Short % of Float | +6.40% |
Source: Nexqual, July 25, 2026 at 03:45 UTC.
Leadership (RVMD)
Revolution Medicines, Inc. is led by Mark A. Goldsmith (age 63), CEO, President & Chairman, per Nexqual as of July 25, 2026 at 03:45 UTC.
| CEO, President & Chairman | Mark A. Goldsmith (age 63) |
|---|---|
| Chief Financial Officer | Jack Anders (age 48) |
| Chief Operating Officer | Margaret A. Horn (age 62) |
| Co-Founder & Chairman of Scientific Advisory Board | Martin D. Burke |
| Chief Scientific Officer | Jan Smith |
Major Backers & Investors (RVMD)
Notable institutional backers of Revolution Medicines, Inc. include Farallon Capital Management LLC, Janus Henderson Group PLC, Baker Bros. Advisors, LP, according to Nexqual as of July 25, 2026 at 03:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Farallon Capital Management LLC | 6.4% |
| Janus Henderson Group PLC | 4.59% |
| Baker Bros. Advisors, LP | 4.49% |
| FMR, LLC | 3.98% |
| Nextech Invest, Ltd. | 3.58% |
| Paradigm Biocapital Advisors LP | 3.13% |
| Wellington Management | 2.84% |
| Fidelity | 1.64% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.26% |
| BlackRock | 5.87% |
Source: Nexqual, July 25, 2026 at 03:45 UTC.
From Revolution Medicines, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
- The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
- Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| RLAY | Relay Therapeutics, Inc. | USD 18.44 | ▼ 4.31% |
| PCVX | Vaxcyte, Inc. | USD 54.66 | ▼ 2.39% |
| BBIO | BridgeBio Pharma, Inc. | USD 84.02 | ▲ 1.65% |
| LEGN | Legend Biotech Corporation | USD 22.22 | ▼ 5.57% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:45 UTC. This page is informational and not investment advice.